United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $29.71 Million Position in Edwards Lifesciences Co. (NYSE:EW)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 422.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 450,233 shares of the medical research company’s stock after purchasing an additional 364,030 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned about 0.07% of Edwards Lifesciences worth $29,711,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in EW. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 1.1% during the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock worth $5,061,277,000 after purchasing an additional 600,994 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. AustralianSuper Pty Ltd increased its position in Edwards Lifesciences by 17.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares during the period. Finally, Ownership Capital B.V. raised its stake in shares of Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after acquiring an additional 34,597 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,133,916.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock valued at $2,744,438 in the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $66.52 on Thursday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $67.47 and a two-hundred day simple moving average of $76.51. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $39.23 billion, a PE ratio of 9.60, a price-to-earnings-growth ratio of 3.70 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the business posted $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on EW. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Wells Fargo & Company decreased their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Robert W. Baird cut their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Barclays reduced their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, Royal Bank of Canada lowered their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.